News
CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...
AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results